Skip to content
Terminus Peptides
Sign inContact
  • Research use only — not for human or veterinary use
  • 67 compound profiles, every source cited
  • 63 research materials listed
  • Prices published, not hidden behind an enquiry
  • Vials and pre-filled pens
  • Dispatched and supported from the UK
  • Every profile states its UK regulatory status

Research profile · Small molecule

L-Carnitine

Also known as Levocarnitine

Clinical — evidence level 4 of 4: Established clinical evidencePrescription only — UK regulatory status: Prescription-only medicine (UK)

Overview

A quaternary amine essential for mitochondrial fatty-acid transport. The injectable form is a prescription-only medicine in the UK.

Category
Small molecule
Highest evidence level identified
Established clinical evidence
Last scientifically reviewed
22 August 2026
Last regulatory review
22 August 2026

Mechanism under investigation

L-carnitine shuttles long-chain fatty acids across the inner mitochondrial membrane: acyl groups are transferred to carnitine by CPT1 on the outer membrane, carried inward by the carnitine–acylcarnitine translocase, and released by CPT2 for beta-oxidation. The body synthesises it from lysine and methionine and absorbs it from meat and dairy; a sodium-dependent transporter, OCTN2, concentrates it in tissue, and inherited defects of that transporter produce primary carnitine deficiency — the condition the licensed medicine exists to treat.

Research areas

  • Fatty acid metabolism

These are fields in which the compound has been investigated. Listing a field is not a statement that anything was demonstrated within it.

Current evidence

In-vitro evidence

Cells, tissues or biochemical systems outside a living organism.

The transport biochemistry is textbook material: the shuttle enzymes, the translocase and the OCTN2 transporter are characterised in molecular detail.

Animal evidence

Studies in living non-human animals.

Extensive, including the OCTN2-deficient mouse reproducing the human deficiency phenotype, and — pointing the other way — work showing gut microbes convert dietary carnitine to trimethylamine, raising pro-atherogenic TMAO in mice.

Human observational evidence

Studies observing people without assigning an intervention.

Large nutritional and metabolic literature. The same microbiome work found omnivores produce more TMAO from carnitine than vegans, and associated plasma carnitine with cardiovascular events in a clinical cohort — an association, not a trial result, but a caution against assuming supplementation is inert.

Clinical-trial evidence

Studies assigning an intervention to human participants.

Decisive only in deficiency states, where replacement is standard of care and the basis of the licence. Across sports performance, weight loss and general fatigue, trials are numerous, small and inconsistent, and meta-analyses disagree with one another depending on inclusion choices.

Study limitations

  • The unambiguous evidence is for treating deficiency; benefit in replete individuals is not established for any popular use.
  • Oral bioavailability is low and saturable, so studies using oral dosing at large amounts mostly document expensive excretion.
  • The TMAO line of evidence suggests chronic high intake may not be neutral, and it remains unresolved a decade on.
  • Performance and weight-loss meta-analyses pool small heterogeneous trials, and their conclusions move with methodology.

UK regulatory context

Prescription-only medicine (UK)

A medicine that may lawfully be supplied in the UK only against a prescription from an appropriate practitioner.

Source: Levocarnitine Paediatric 30% oral solution — Summary of Product Characteristics (opens medicines.org.uk in a new tab) (electronic Medicines Compendium)

Regulatory classification is jurisdiction-specific. A compound authorised elsewhere is not thereby authorised in the UK, and a supplier’s description of a substance does not determine how it is classified in law. See safety and regulation for the framework and the authoritative sources.

Safety and interpretation

The regulatory position turns on route and presentation, not on the molecule: oral carnitine is sold lawfully as a food supplement, while levocarnitine medicinal products — including the injectable — are prescription-only medicines licensed for carnitine deficiency. Injectable use belongs to metabolic medicine and dialysis units. The molecule itself is well tolerated at ordinary intakes, with gastrointestinal upset and a fishy odour at high doses; the open question over chronic high intake is the microbiome-generated TMAO association. Any injectable use outside the licensed products has no safety framework at all.

References